Long-Acting Injectable and Implantable Dosage Forms: A Paradigm Shift in Chronic Disease Therapy
Abstract
The global burden of chronic diseases such as diabetes, HIV, schizophrenia, and hormonal imbalances continues to grow,
placing immense pressure on healthcare systems and patients alike. Traditional oral or short-acting parenteral therapies
are often hindered by poor adherence, leading to suboptimal outcomes, resistance development, and increased morbidity.
Long-acting injectable and implantable dosage forms offer a transformative approach to overcoming these limitations. By
providing sustained therapeutic effects over extended periods, these delivery systems represent a significant advancement
in chronic disease management. This review explores the principles, mechanisms, clinical applications, benefits, limitations,
and future potential of these advanced drug delivery platforms
References
1. Dashputre NL, Laddha UD, Ahire ED, Bandawane DD, Patil SB, Kadam JD. Overview of Chronic Diseases. Nov Drug Deliv Syst Manag Chronic Dis. Apple Academic Press; 2024. p. 3–35.
2. Khunti K, Chudasama Y V, Gregg EW, Kamkuemah M, Misra S, Suls J, et al. Diabetes and multiple long-term conditions: a review of our current global health challenge. Diabetes Care. 2023;46:2092–101.
3. Konstantinou P, Kassianos AP, Georgiou G, Panayides A, Papageorgiou A, Almas I, et al. Barriers, facilitators, and interventions for medication adherence across chronic conditions with the highest non-adherence rates: a scoping review with recommendations for intervention development. Transl Behav Med. 2020;10:1390–8.
4. Vogeli C, Shields AE, Lee TA, Gibson TB, Marder WD, Weiss KB, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med. 2007;22:391–5.
5. Bauer A, Berben P, Chakravarthi SS, Chattorraj S, Garg A, Gourdon B, et al. Current state and opportunities with long-acting injectables: industry perspectives from the innovation and quality consortium “long-acting injectables” working group. Pharm Res. 2023;40:1601–31.
6. Benjamin DM. Reducing medication errors and increasing patient safety: case studies in clinical pharmacology. J Clin Pharmacol. 2003;43:768–83.
7. McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J Clin Psychiatry. 2006;67:15–
8. Altreuter DH, Kirtane AR, Grant T, Kruger C, Traverso G, Bellinger AM. Changing the pill: developments toward the promise of an ultra-long-acting gastroretentive dosage form. Expert Opin Drug Deliv. 2018;15:1189–98.
9. Owen A, Rannard S. Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. Adv Drug Deliv Rev. 2016;103:144–56.
10. Kim Y-C, Min KA, Jang D-J, Ahn TY, Min JH, Yu BE, et al. Practical approaches on the long-acting injections. J Pharm Investig. 2020;50:147–57.
11. Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:1–17.
12. Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021;57:106220.
13. Kaunitz AM. Injectable long-acting contraceptives. Clin Obstet Gynecol. 2001;44:73–91.
14. Davis CS, Fleming JW, Malinowski SS, Brown MA, Fleming LW. Ultra-long-acting insulins: a review of efficacy, safety, and implications for practice. J Am Assoc Nurse Pract. 2018;30:373–80.
15. O’Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;336:144–58.
16. Gonella A, Grizot S, Liu F, López Noriega A, Richard J. Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules. Expert Opin Drug Deliv. 2022;19:927–44.
17. Alidori S, Subramanian R, Holm R. Patient-centric long-acting injectable and implantable Platforms─ An industrial perspective. Mol Pharm. 2024;21:4238–58.
18. Bassand C, Villois A, Gianola L, Laue G, Ramazani F, Riebesehl B, et al. Smart design of patient-centric long-acting products: from preclinical to marketed pipeline trends and opportunities. Expert Opin Drug Deliv. 2022;19:1265–83.
19. Jindal AB, Bhide AR, Salave S, Rana D, Benival D. Long-acting parenteral drug delivery systems for the treatment of chronic diseases. Adv Drug Deliv Rev. 2023;198:114862.
20. Stevenson CL, Santini Jr JT, Langer R. Reservoir-based drug delivery systems utilizing microtechnology. Adv Drug Deliv Rev. 2012;64:1590–602.
21. Rathore G, Singh RP. Transforming Disease Management: The Clinical Benefits of Long-Acting Injectable Drug Delivery Systems. Intell Hosp. 2025;100001.
